Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up

The study objective was to evaluate the intraocular pressure (IOP) and medication-lowering effect of 2 second-generation trabecular micro-bypass stents in eyes with open-angle glaucoma (OAG) on one preoperative medication. Fifty-seven qualified phakic eyes with OAG on 1 medication, preoperative medicated IOP of 18-30 mmHg, and preoperative unmedicated (post-washout) IOP of 22-38 mmHg underwent implantation of 2 second-generation trabecular micro-bypass stents in a standalone procedure. Evaluations included IOP, best-corrected visual acuity, medication use, fundus and slit lamp examinations, visual field, cup to disc ratio, pachymetry, and complications and interventions. Subjects have been followed for 18 months, and follow-up is ongoing. At Month 12 postoperative, 100% of eyes had achieved an IOP reduction aeyen20% (100% had IOP aecurrency sign18 mmHg and 67% had IOP aecurrency sign15 mmHg) without medication versus preoperative unmedicated IOP, and 75% had IOP reduction aeyen20% without medication versus preoperative medicated IOP. The Month 12 mean unmedicated IOP had decreased by 42%, to 14.2 +/- 1.9 mmHg vs 24.4 +/- 1.3 mmHg preoperatively, and this reduction was maintained through 18 months (14.4 +/- 2.1 mmHg). A high safety profile was observed. In this prospective, open-label, single-arm study, the standalone implantation of two second-generation trabecular micro-bypass stents in OAG patients on 1 preoperative medication resulted in IOP reduction to aecurrency sign15 mmHg and elimination of medication through 18 months, with favorable safety. ClinicalTrials.gov identifier, NCT02868190. Glaukos Corporation, San Clemente, CA.